Local hyperthermia combined with CTLA-4 blockade induces both local and abscopal effects in a murine breast cancer model

References

• Akinyemiju TF, Al Lami FH, Alam T, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–1568.
   PubMed Web of Science ®Google Scholar
• Weigelt B, Peterse JL, van’t Veer LJ. Breast cancer metastasis: markers and models. Nat Rev Cancer. 2005;5(8):591–602.
   PubMed Web of Science ®Google Scholar
• Swain SM, Sorace RA, Bagley CS, et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced nonmetastatic breast cancer. Cancer Res. 1987;47(14):3889–3894.
   PubMed Web of Science ®Google Scholar
• Overgaard J, Gonzalez DG, Hulshof MC, et al. Randomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic Oncology. Lancet. 1995;345(8949):540–543.
   PubMed Web of Science ®Google Scholar
• Masunaga S, Hiraoka M, Takahashi M, et al. Clinical results of thermoradiotherapy for locally advanced and/or recurrent breast cancer-comparison of results with radiotherapy alone. Int J Hyperthermia. 1990;6(3):487–497.
   PubMed Web of Science ®Google Scholar
• Costa MA, Fardilha C, Fonseca G, et al. Radiotherapy and hyperthermia in the treatment of locoregional recurrent cancer-Report of the first patients treated in portugal. Sci J Clin Med. 2019;8(1):1–5.
   Google Scholar
• Ohtake M, Umemura M, Sato I, et al. Hyperthermia and chemotherapy using Fe(Salen) nanoparticles might impact glioblastoma treatment. Sci Rep. 2017;7:42783.
   PubMed Web of Science ®Google Scholar
• Vujaskovic Z, Kim DW, Jones E, et al. A phase I/II study of neoadjuvant liposomal doxorubicin, paclitaxel, and hyperthermia in locally advanced breast cancer. Int J Hyperthermia. 2010;26(5):514–521.
   PubMed Web of Science ®Google Scholar
• Dudar TE, Jain RK. Differential response of normal and tumor microcirculation to hyperthermia. Cancer Res. 1984;44(2):605–612.
   PubMed Web of Science ®Google Scholar
• Toraya-Brown S, Fiering S. Local tumour hyperthermia as immunotherapy for metastatic cancer. Int J Hyperthermia. 2014;30(8):531–539.
   PubMed Web of Science ®Google Scholar
• Zhang HG, Mehta K, Cohen P, et al. Hyperthermia on immune regulation: a temperature’s story. Cancer Lett. 2008;271(2):191–204.
   PubMed Web of Science ®Google Scholar
• Skitzki JJ, Repasky EA, Evans SS. Hyperthermia as an immunotherapy strategy for cancer. Curr Opin Investig Drugs. 2009;10(6):550–558.
   PubMedGoogle Scholar
• Bendz H, Ruhland SC, Pandya MJ, et al. Human heat shock protein 70 enhances tumor antigen presentation through complex formation and intracellular antigen delivery without innate immune signaling. J Biol Chem. 2007;282(43):31688–31702.
   PubMed Web of Science ®Google Scholar
• Todryk S, Melcher AA, Hardwick N, et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake1. J Immunol. 1999;163(3):1398–1408.
   PubMed Web of Science ®Google Scholar
• Rovere-Querini P, Capobianco A, Scaffidi P, et al. HMGB1 is an endogenous immune adjuvant released by necrotic cells. EMBO Rep. 2004;5(8):825–830.
   PubMed Web of Science ®Google Scholar
• Rovere-Querini P, Capobianco A, Scaffidi P, et al. Local hyperthermia combined with radiotherapy and-/or chemotherapy: recent advances and promises for the future. Cancer Treat Rev. 2004;41(9):742–753.
   Google Scholar
• Topalian SL, Drake CG, Pardoll DW. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
   PubMed Web of Science ®Google Scholar
• Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1(5):405–413.
   PubMed Web of Science ®Google Scholar
• Lee KM, Chuang E, Griffin M, et al. Molecular basis of T cell inactivation by CTLA-4. Science. 1998;282(5397):2263–2266.
   PubMed Web of Science ®Google Scholar
• Soldevilla MM, Villanueva H, Meraviglia-Crivelli D, et al. ICOS costimulation at the tumor site in combination with CTLA-4 blockade therapy elicits strong tumor immunity. Mol Ther. 2019;27(11):1878–1891.
   PubMed Web of Science ®Google Scholar
• Elsas AV, Hurwitz AA. and, Allison JP. Combination immunotherapy of B16 melanoma using anti-cytotoxic t lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J Exp Med. 1999;190(3):355–366.
   PubMed Web of Science ®Google Scholar
• Affolter T, Llewellyn HP, Bartlett DW, et al. Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS One. 2019;14(5):e0217276.
   PubMed Web of Science ®Google Scholar
• Nolan E, Savas P, Policheni AN, et al. Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer. Sci Transl Med. 2017;9(393):eaal4922.
   PubMed Web of Science ®Google Scholar
• Formenti SC, Rudqvist NP, Golden E, et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–1851.
   PubMed Web of Science ®Google Scholar
• Liu Y, Dong Y, Kong L, et al. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11(1):104.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Yasui T, Minami K, et al. Carbon ion irradiation enhances the antitumor efficacy of dual immune checkpoint blockade therapy both for local and distant sites in murine osteosarcoma. Oncotarget. 2019;10(6):633–646.
   PubMedGoogle Scholar
• Chamoto K, Chowdhury PS, Kumar A, et al. Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity. Proc Natl Acad Sci USA. 2017;114(5):E761–E770.
   PubMed Web of Science ®Google Scholar
• Brinkmann V, Davis MD, Heise CE, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277(24):21453–21457.
   PubMed Web of Science ®Google Scholar
• Chen T, Guo J, Han C, et al. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182(3):1449–1459.
   PubMed Web of Science ®Google Scholar
• Sen K, Sheppe AEF, Singh I, et al. Exosomes released by breast cancer cells under mild hyperthermic stress possess immunogenic potential and modulate polarization in vitro in macrophages. Int J Hyperthermia. 2020;37(1):696–710.
   PubMed Web of Science ®Google Scholar
• Dewey WC, Hopwood LE, Sapareto SA, et al. Cellular responses to combinations of hyperthermia and radiation. Radiology. 1977;123(2):463–474.
   PubMed Web of Science ®Google Scholar
• Ando K, Suzuki Y, Kaminuma T, et al. Tumor-specific CD8-positive T cell-mediated antitumor immunity is implicated in the antitumor effect of local hyperthermia. Int J Hyperthermia. 2018;35(1):226–231.
   PubMed Web of Science ®Google Scholar
• Chao Y, Chen G, Liang C, et al. Iron nanoparticles for low-power local magnetic hyperthermia in combination with immune checkpoint blockade for systemic antitumor therapy. Nano Lett. 2019;19(7):4287–4296.
   PubMed Web of Science ®Google Scholar
• Chi MS, Yang KL, Chang YC, et al. Comparing the effectiveness of combined external beam radiation and hyperthermia versus external beam radiation alone in treating patients with painful bony metastases: a phase 3 prospective, randomized, controlled trial. Int J Radiat Oncol Biol Phys. 2018;100(1):78–87.
   PubMed Web of Science ®Google Scholar
• Oei AL, Korangath P, Mulka K, et al. Enhancing the abscopal effect of radiation and immune checkpoint inhibitor therapies with magnetic nanoparticle hyperthermia in a model of metastatic breast cancer. Int J Hyperthermia. 2019;36(1):47–63.
   PubMed Web of Science ®Google Scholar
• Victor CT, Rech AJ, Maity A, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373–377.
   PubMed Web of Science ®Google Scholar
• Vanpouille-Box C, Alard A, Aryankalayil MJ, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity. Nat Commun. 2017;8:15618.
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Cheadle EJ, Popple AL, et al. Fractionated radiation therapy stimulates antitumor immunity mediated by both resident and infiltrating polyclonal T-cell populations when combined with PD-1 blockade. Clin Cancer Res. 2017;23(18):5514–5526.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Yasui T, Minami K, et al. Radiation enhanced the local and distant anti-tumor efficacy in dual immune checkpoint blockade therapy in osteosarcoma. PLoS One. 2017;12(12):e0189697.
   PubMed Web of Science ®Google Scholar